DALLAS, Aug. 10, 2009 (GLOBE NEWSWIRE) -- Kendall Law Group (www.kendalllawgroup.com) is investigating the proposed acquisition of MTS Medication Technologies, Inc. (Nasdaq:MTSI) by Excellere Partners, LLC. On August 8, 2009, Excellere Partners announced that it had entered into a definitive merger agreement with MTSI, where MTSI shareholders would receive $5.75 per share. This price per share represents virtually no premium over the closing stock of MTSI ($5.70) just prior to the announcement. As recently as June 17, 2009, the company's shares traded at $6.24. In addition, approximately 30% of MTSI shares owned by the CEO, President and certain other members of the senior management team of MTSI will be exchanged for cash and shares of the newly formed company.
The firm's investigation concerns whether the consideration to be paid to MTSI shareholders is grossly unfair, inadequate, and substantially below the fair or inherent value of MTSI and whether the directors and special committee members of MTSI may have breached their fiduciary duties by not acting in MTSI shareholders' best interests in connection with the sale process of MTSI.
For information about your rights as a MTSI shareholder, contact attorney Hamilton Lindley at 877-744-3728 or by email at hlindley@kendalllawgroup.com. Kendall Law Group is led by a former federal judge and former U.S. Attorney. The firm has nationwide experience representing investors in mergers and acquisitions.
The Kendall Law Group, LLP logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6273